Gavin Stewart Dawe - Facts
Dr Gavin Stewart Dawe’s laboratory investigates the neuropharmacology of drugs for age-related neuroscience and mental
health disorders with systems neurobiology, behavioural neuroscience, electrophysiological and optogenetic approaches.
Significant research contributions including discovering fetal microchimerism in maternal brains, advancing understanding
of the signalling functions of the amyloid precursor protein (APP) intracellular domain (AICD), and elucidating functions
of the nucleus incertus and the neuropeptide relaxin-3.
- Recent research in his laboratory focuses on peptide pharmacology. He is developing novel pepditomimetics
and stapled peptides as receptor agonists/antagonists and inhibitors of protein interactions. Current projects
focus on developing (1) relaxin-3 and neuropeptide Y receptor ligands for treatment of obesity, metabolic syndrome,
anxiety and depression; and (2) inhibitors of the binding of APP domains for Alzheimer’s disease and associated neurological disorders.
- Discipline: Medical Science
- Area of Research: Neuropharmacology / Neuroscience
- Research/Constancy Projects: (Ongoing/Completed)
- Title: Stapled relaxin-3 B- chain peptides as novel RXFP3 agonists and antagonists
- Funding Agency: Ministry of Education AcRF Tier 1 (Singapore)
- Current R&D Activities:Dr. Gavin Stewart Dawe's lab investigates peptide pharmacology for neurological and neuropsychiatric disorders. They develop
pepditomimetics and stapled peptides as receptor agonists/antagonists and inhibitors of protein interactions.
Current projects focus on (1) relaxin-3 and neuropeptide Y for obesity, metabolic syndrome, anxiety and
depression; and (2) inhibitors amyloid precursor protein (APP) domain binding for Alzheimer’s disease. We test
our ligands with receptor/target binding and activation/inhibition assays, in vitro and in vivo electrophysiology,
optogenetics and behavioural neuroscience.
Dr Gavin Stewart Dawe received his BSc (Hons) in Neuroscience from the University of Edinburgh, United Kingdom in 1990
and his PhD in Pharmacology from the Institute of Psychiatry, King’s College London, United Kingdom in 1995.
After postdoctoral research at the Institute of Psychiatry, he worked with ReNeuron Limited and Eli Lilly and
Company before joining the National University of Singapore (NUS). He is currently an Associate Professor,
Deputy Head of Department and Education Director at the Department of Pharmacology, Yong Loo Lin School of Medicine, NUS.
- At NUS he also serves as Core Leader of the Neuroscience Phenotyping Core; as a member of the NUS Graduate School
for Integrative Sciences and Engineering; and as a Principal Investigator under the Neurobiology and Ageing Programme,
Life Sciences Institute, and the Singapore Institute for Neurotechnology (SINAPSE). He is currently Vice President of the
Singapore Neuroscience Association and of the Pharmacological Society (Singapore).